600211 Stock Overview
Tibet Rhodiola Pharmaceutical Holding Co. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Tibet Rhodiola Pharmaceutical Holding Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥35.99 |
| 52 Week High | CN¥45.12 |
| 52 Week Low | CN¥26.95 |
| Beta | 1.09 |
| 1 Month Change | -4.59% |
| 3 Month Change | -4.61% |
| 1 Year Change | 18.78% |
| 3 Year Change | 13.31% |
| 5 Year Change | 87.15% |
| Change since IPO | 396.94% |
Recent News & Updates
These 4 Measures Indicate That Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Is Using Debt Safely
Jan 02
Investors Holding Back On Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211)
Nov 27Recent updates
These 4 Measures Indicate That Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Is Using Debt Safely
Jan 02Investors Holding Back On Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211)
Nov 27At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?
Sep 25Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt
Sep 02Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price
Jul 29Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital
Jul 12Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly
May 21Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings
May 03Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive
Mar 22Shareholder Returns
| 600211 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 0.3% | 1.0% | 0.07% |
| 1Y | 18.8% | -3.6% | 18.4% |
Return vs Industry: 600211 exceeded the CN Healthcare industry which returned -6.5% over the past year.
Return vs Market: 600211 exceeded the CN Market which returned 15.4% over the past year.
Price Volatility
| 600211 volatility | |
|---|---|
| 600211 Average Weekly Movement | 3.2% |
| Healthcare Industry Average Movement | 5.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 600211 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600211's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 601 | Yuan Dong Guo | www.xzyy.cn |
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceuticals in China and internationally. The company offers biological products, tibetan medicine, chinese medicine, and chemical medicine products. It also offers capsules, preparations, granules, and coatings for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds, etc. Tibet Rhodiola Pharmaceutical Holding Co. was founded in 1999 and is based in Lhasa, China.
Tibet Rhodiola Pharmaceutical Holding Co. Fundamentals Summary
| 600211 fundamental statistics | |
|---|---|
| Market cap | CN¥11.60b |
| Earnings (TTM) | CN¥737.44m |
| Revenue (TTM) | CN¥2.94b |
15.7x
P/E Ratio3.9x
P/S RatioIs 600211 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600211 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.94b |
| Cost of Revenue | CN¥158.60m |
| Gross Profit | CN¥2.78b |
| Other Expenses | CN¥2.05b |
| Earnings | CN¥737.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 15, 2025
| Earnings per share (EPS) | 2.29 |
| Gross Margin | 94.61% |
| Net Profit Margin | 25.07% |
| Debt/Equity Ratio | 14.4% |
How did 600211 perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield67%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 10:00 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tibet Rhodiola Pharmaceutical Holding Co. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Weina Jiang | Everbright Securities Co. Ltd. |
| Wen Liang Cui | Founder Securities Co., Ltd. |
| Zhouyu Deng | Guosen Securities Co., Ltd. |